Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and Neurotrophic Keratitis
16. Dezember 2024 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and...
Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma
13. November 2023 08:00 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1 clinical trial of investigational cancer immunotherapy PV-10 (rose bengal...
Provectus Biopharmaceuticals Presents Data from PV-10® Treatment of Metastatic Uveal Melanoma Patients in Two Oral Presentations at 2022 International Society of Ocular Oncology (ISOO) Congress
30. Juni 2022 13:42 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, June 30, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that updated data from the Company’s initial expansion cohort of patients with uveal melanoma metastatic to...
Provectus Biopharmaceuticals Presents Multiple Metabolic Complete Responders from PV-10® Treatment of Early-Stage Metastatic Uveal Melanoma Patients at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
08. Juni 2022 07:00 ET
|
Provectus Biopharmaceuticals Inc.
29% of M1a patients achieved metabolic complete response (mCR)mCR patients alive up to >4 years after start of PV-10 treatmentPET tumor response assessment more accurate than 2D EASL or...
Delcath Announces First Quarter 2020 Results
15. Mai 2020 06:30 ET
|
Delcath Systems, Inc.
Highlights include $22 million public offering, uplisting to Nasdaq, Pivotal Registration Trial enrollment completed, and Pivotal Registration Topline Data Expected in 2020 NEW YORK, May 15, 2020 ...
Delcath Systems Closes $22.0 Million Public Offering of Common Stock
05. Mai 2020 16:05 ET
|
Delcath Systems, Inc.
NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver,...
Delcath Systems Announces Pricing of $22 Million Public Offering and Uplisting to the Nasdaq Capital Market
01. Mai 2020 10:17 ET
|
Delcath Systems, Inc.
NEW YORK, May 01, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the...
Delcath Systems Elects Seasoned Finance and Capital Markets Executive Elizabeth Czerepak to its Board of Directors
19. Februar 2020 08:30 ET
|
Delcath Systems, Inc.
NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that...
Delcath Completes Enrollment in its United States Registration Pivotal Trial (FOCUS) Investigating Melphalan/HDS in the Treatment of Patients with Unresectable Hepatic-Dominant Ocular Melanoma
13. Januar 2020 08:30 ET
|
Delcath Systems, Inc.
NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today...
Delcath Systems Announces 1-for-700 Reverse Stock Split to be Effective on December 24, 2019
19. Dezember 2019 08:30 ET
|
Delcath Systems, Inc.
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that...